What is the risk for a new breast cancer diagnosis in the other breast for women with a BRCA1, BRCA2 or TP53 mutation?
https://www.facingourrisk.org/XRAY/risk-for-second-diagnosis-after-breast-cancer-with-inherited-mutations
Full article: https://www.mdpi.com/2072-6694/12/2/378
For women who have been diagnosed with breast cancer, knowing their risk of breast cancer in the other (contralateral) breast can help them make decisions about surgery and screening. This study shows that women with an inherited mutation in BRCA1, BRCA2 or TP53 have an increased risk for contralateral breast cancer. This risk is highest in women with a TP53 mutation. (6/6/20)
Questions To Ask Your Health Care Provider
- Given my personal and family history and mutation status, what is my risk of contralateral breast cancer?
- What are the pros and cons of risk-reducing mastectomy in my contralateral breast?
- If I have a mutation and choose not to have risk-reducing mastectomy of my contralateral breast, what type of surveillance do you recommend and how often?
- Do you recommend that I have genetic testing?
- How do I get genetic testing?
Open Clinical Trials
The following are breast cancer screening or prevention studies enrolling people at high risk for breast cancer:
- The Risk Factor Analysis of Hereditary Breast and Ovarian Cancer In Women with BRCA1, BRCA2 or PALB2 Mutations. This study seeks to improve researchers’ understanding of how hormonal, reproductive and lifestyle factors may be associated with cancer in high-risk people.
- NCT02620852: Women Informed to Screen Depending on Measures of Risk (WISDOM) study. The goal of this study is to determine whether breast cancer screening can be improved by personalizing each woman’s mammogram schedule compared to the current one-size-fits-all annual approach.
-
NCT04674306: Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer. This study is testing a new vaccine to lower the risk of breast cancer in high-risk women with an inherited mutation in BRCA1, BRCA2 or PALB2.
Additional risk-management clinical trials for people at high risk for breast cancer may be found here.
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.